Table 1: Sales by Segment 1 Table 2: Sales by Geographic Area 2 Table 3: Sales of Key Products/Franchises 3 - 7 Table 4: Condensed Consolidated Statement of Earnings - QTD 8 Table 5: Condensed Consolidated Statement of Earnings - YTD 9 Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 10 Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 11 Table 8: Non-GAAP Adjusted Net Earnings 12 Table 9: Non-GAAP P&L by Segment Reconciliation 2026 - QTD 13 Table 10: Non-GAAP P&L by Segment Reconciliation 2025 - QTD 14 Table 11: Non-GAAP P&L by Segment Reconciliation 2026 - YTD 15 Table 12: Non-GAAP P&L by Segment Reconciliation 2025 - YTD 16 Third Quarter 2026 Other Financial Disclosures Table of Contents -- 1 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2026 2025 Total Operations Currency 2026 2025 Total Operations Currency Sales to customers by segment of business Innovative Medicine U.S. 10,447 $ 9,402 11.1 % 11.1 - 29,297 $ 26,655 9.9 % 9.9 - International 6,310 6,161 2.4 3.0 (0.6) 19,270 17,983 7.2 3.6 3.6 16,757 15,563 7.7 7.9 (0.2) 48,567 44,638 8.8 7.4 1.4 MedTech U.S. 4,512 4,306 4.8 4.8 - 13,525 12,902 4.8 4.8 - International 4,130 4,124 0.1 0.1 0.0 12,679 12,089 4.9 2.2 2.7 8,642 8,430 2.5 2.5 0.0 26,204 24,991 4.9 3.5 1.4 U.S. 14,959 13,708 9.1 9.1 - 42,822 39,557 8.3 8.3 - International 10,440 10,285 1.5 1.8 (0.3) 31,949 30,072 6.2 3.0 3.2 Worldwide 25,399 $ 23,993 5.9 % 6.0 (0.1) 74,771 $ 69,629 7.4 % 6.0 1.4 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. THIRD QUARTER NINE MONTHS Percent Change -- 2 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2026 2025 Total Operational Currency 2026 2025 Total Operational Currency Sales to customers by geographic area U.S. 14,959 $ 13,708 9.1 % 9.1 - 42,822 $ 39,557 8.3 % 8.3 - Europe 5,405 5,440 (0.6) 1.0 (1.6) 16,979 15,937 6.5 2.3 4.2 Western Hemisphere excluding U.S. 1,385 1,231 12.5 8.0 4.5 3,987 3,604 10.6 4.5 6.1 Asia-Pacific, Africa 3,650 3,614 1.0 1.0 0.0 10,983 10,531 4.3 3.6 0.7 International 10,440 10,285 1.5 1.8 (0.3) 31,949 30,072 6.2 3.0 3.2 Worldwide 25,399 $ 23,993 5.9 % 6.0 (0.1) 74,771 $ 69,629 7.4 % 6.0 1.4 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. THIRD QUARTER NINE MONTHS Percent Change -- 3 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS INNOVATIVE MEDICINE SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency ONCOLOGY US 4,267 $ 3,468 23.0% 23.0% - 11,951 $ 9,866 21.1% 21.1% - Intl 3,335 3,060 9.0% 9.5% (0.5)% 10,030 8,652 15.9% 11.9% 4.0% WW 7,602 6,529 16.4% 16.7% (0.3)% 21,981 18,519 18.7% 16.8% 1.9% DARZALEX US 2,528 2,088 21.1% 21.1% - 7,171 5,934 20.9% 20.9% - Intl 1,711 1,584 8.0% 8.5% (0.5)% 5,239 4,514 16.1% 11.9% 4.2% WW 4,239 3,672 15.4% 15.6% (0.2)% 12,410 10,448 18.8% 17.0% 1.8% CARVYKTI US 472 396 19.4% 19.4% - 1,377 1,072 28.5% 28.5% - Intl 238 128 85.3% 84.1% 1.2% 587 260 * * * WW 710 524 35.5% 35.2% 0.3% 1,964 1,332 47.4% 45.5% 1.9% TECVAYLI US 236 115 * * - 549 334 64.4% 64.4% - Intl 77 62 24.0% 25.9% (1.9)% 225 160 40.6% 37.7% 2.9% WW 312 177 76.6% 77.3% (0.7)% 774 494 56.7% 55.7% 1.0% TALVEY US 112 85 31.6% 31.6% - 325 235 38.1% 38.1% - Intl 59 37 62.9% 66.9% (4.0)% 172 79 * * * WW 171 122 40.9% 42.1% (1.2)% 497 314 58.3% 57.5% 0.8% RYBREVANT / LAZCLUZE US 201 136 47.9% 47.9% - 566 388 46.1% 46.1% - Intl 119 61 94.5% 98.3% (3.8)% 300 130 * * * WW 320 198 62.3% 63.5% (1.2)% 866 518 67.4% 67.5% (0.1)% ERLEADA US 423 378 11.8% 11.8% - 1,161 1,048 10.8% 10.8% - Intl 600 558 7.7% 7.7% 0.0% 1,806 1,567 15.3% 10.8% 4.5% WW 1,023 936 9.4% 9.4% 0.0% 2,967 2,615 13.5% 10.8% 2.7% IMBRUVICA US 145 211 (31.6)% (31.6)% - 437 685 (36.3)% (36.3)% - Intl 420 483 (13.2)% (12.6)% (0.6)% 1,386 1,453 (4.7)% (8.7)% 4.0% WW 563 695 (18.8)% (18.4)% (0.4)% 1,822 2,139 (14.8)% (17.5)% 2.7% OTHER ONCOLOGY (3) US 149 61 * * - 365 171 * * - Intl 111 147 (24.4)% (23.9)% (0.5)% 314 488 (35.7)% (36.0)% 0.3% WW 262 207 26.3% 26.7% (0.4)% 680 659 3.2% 2.9% 0.3% See footnotes at end of schedule % Change % Change -- 4 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency IMMUNOLOGY US 2,804 $ 2,676 4.8% 4.8% - 7,031 $ 7,377 (4.7)% (4.7)% - Intl 1,417 1,493 (5.1)% (4.8)% (0.3)% 4,414 4,492 (1.7)% (4.9)% 3.2% WW 4,221 4,168 1.3% 1.4% (0.1)% 11,445 11,868 (3.6)% (4.8)% 1.2% TREMFYA US 1,772 989 79.1% 79.1% - 4,279 2,384 79.5% 79.5% - Intl 624 434 43.7% 43.4% 0.3% 1,771 1,181 49.9% 44.7% 5.2% WW 2,396 1,424 68.3% 68.2% 0.1% 6,050 3,566 69.7% 67.9% 1.8% SIMPONI / SIMPONI ARIA US 269 309 (13.2)% (13.2)% - 798 906 (11.9)% (11.9)% - Intl 299 377 (20.6)% (20.3)% (0.3)% 1,035 1,130 (8.4)% (11.4)% 3.0% WW 568 687 (17.3)% (17.1)% (0.2)% 1,833 2,036 (10.0)% (11.6)% 1.6% REMICADE US 258 326 (20.8)% (20.8)% - 742 923 (19.6)% (19.6)% - US Exports (4) 12 19 (37.1)% (37.1)% - 40 63 (36.6)% (36.6)% - Intl 124 132 (6.2)% (7.5)% 1.3% 372 413 (9.8)% (12.9)% 3.1% WW 394 476 (17.3)% (17.6)% 0.3% 1,154 1,398 (17.5)% (18.4)% 0.9% STELARA US 368 1,022 (64.0)% (64.0)% - 924 3,081 (70.0)% (70.0)% - Intl 349 549 (36.5)% (35.5)% (1.0)% 1,188 1,768 (32.8)% (34.9)% 2.1% WW 716 1,570 (54.4)% (54.0)% (0.4)% 2,112 4,848 (56.4)% (57.2)% 0.8% OTHER IMMUNOLOGY US 126 12 * * - 249 21 * * - Intl 21 0 * * * 48 0 * * * WW 147 12 * * * 297 21 * * * NEUROSCIENCE US 1,733 1,367 26.8% 26.8% - 4,886 3,712 31.6% 31.6% - Intl 642 658 (2.4)% (1.7)% (0.7)% 2,001 2,011 (0.5)% (3.0)% 2.5% WW 2,375 2,024 17.3% 17.6% (0.3)% 6,887 5,722 20.3% 19.5% 0.8% SPRAVATO US 559 405 37.9% 37.9% - 1,479 1,047 41.3% 41.3% - Intl 66 53 22.7% 21.4% 1.3% 197 146 34.8% 28.1% 6.7% WW 624 459 36.1% 36.0% 0.1% 1,676 1,193 40.5% 39.7% 0.8% CAPLYTA (5) US 398 240 66.1% 66.1% - 1,029 451 * * - Intl - - - - - - - - - - WW 398 240 66.1% 66.1% - 1,029 451 * * - INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 739 664 11.4% 11.4% - 2,235 2,021 10.6% 10.6% - Intl 258 267 (3.0)% (2.4)% (0.6)% 816 804 1.5% (0.8)% 2.3% WW 998 929 7.3% 7.5% (0.2)% 3,051 2,824 8.0% 7.4% 0.6% CONCERTA / Methylphenidate US 6 14 (56.3)% (56.3)% - 40 76 (47.3)% (47.3)% - Intl 138 127 8.1% 8.9% (0.8)% 386 376 2.4% 1.1% 1.3% WW 143 140 2.1% 2.9% (0.8)% 425 452 (5.9)% (7.0)% 1.1% OTHER NEUROSCIENCE US 32 46 (30.6)% (30.6)% - 104 119 (12.6)% (12.6)% - Intl 180 210 (14.3)% (13.1)% (1.2)% 602 684 (12.0)% (14.5)% 2.5% WW 212 256 (17.3)% (16.2)% (1.1)% 706 803 (12.1)% (14.2)% 2.1% See footnotes at end of schedule % Change % Change -- 5 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency PULMONARY HYPERTENSION (PH) US 588 $ 815 (27.8)% (27.8)% - 2,233 $ 2,358 (5.3)% (5.3)% - Intl 309 300 2.9% 4.1% (1.2)% 942 895 5.2% 2.9% 2.3% WW 897 1,115 (19.5)% (19.2)% (0.3)% 3,175 3,253 (2.4)% (3.0)% 0.6% UPTRAVI US 383 392 (2.2)% (2.2)% - 1,154 1,139 1.3% 1.3% - Intl 100 92 8.9% 8.4% 0.5% 306 272 12.7% 7.9% 4.8% WW 483 484 (0.1)% (0.2)% 0.1% 1,460 1,411 3.5% 2.6% 0.9% OPSUMIT / OPSYNVI US 193 409 (52.8)% (52.8)% - 1,042 1,175 (11.3)% (11.3)% - Intl 179 168 5.9% 7.8% (1.9)% 538 507 6.0% 4.4% 1.6% WW 372 578 (35.7)% (35.2)% (0.5)% 1,580 1,682 (6.1)% (6.6)% 0.5% OTHER PULMONARY HYPERTENSION US 12 13 (7.3)% (7.3)% - 37 44 (15.5)% (15.5)% - Intl 30 39 (23.8)% (21.2)% (2.6)% 98 116 (15.6)% (15.3)% (0.3)% WW 42 53 (19.7)% (17.7)% (2.0)% 135 160 (15.6)% (15.4)% (0.2)% INFECTIOUS DISEASES (ID) US 317 326 (2.7)% (2.7)% - 959 961 (0.2)% (0.2)% - Intl 496 501 (1.2)% (0.1)% (1.1)% 1,506 1,472 2.3% (1.7)% 4.0% WW 813 829 (1.8)% (1.1)% (0.7)% 2,465 2,434 1.3% (1.1)% 2.4% EDURANT / rilpivirine US 5 7 (31.6)% (31.6)% - 15 21 (30.1)% (30.1)% - Intl 382 378 1.0% 2.4% (1.4)% 1,131 1,082 4.5% 0.6% 3.9% WW 386 385 0.4% 1.8% (1.4)% 1,145 1,103 3.8% 0.0% 3.8% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 307 315 (2.5)% (2.5)% - 937 932 0.6% 0.6% - Intl 74 81 (8.9)% (7.7)% (1.2)% 259 264 (1.9)% (6.2)% 4.3% WW 381 397 (3.8)% (3.6)% (0.2)% 1,196 1,196 0.0% (0.9)% 0.9% OTHER INFECTIOUS DISEASES US 5 4 29.9% 29.9% - 7 8 (11.4)% (11.4)% - Intl 40 42 (6.2)% (7.9)% 1.7% 116 126 (8.0)% (11.7)% 3.7% WW 46 47 (3.0)% (4.5)% 1.5% 124 135 (8.2)% (11.7)% 3.5% CARDIOVASCULAR / METABOLISM / OTHER (CVM) US 736 750 (1.9)% (1.9)% - 2,235 2,381 (6.1)% (6.1)% - Intl 112 149 (24.3)% (23.8)% (0.5)% 378 461 (17.9)% (20.9)% 3.0% WW 849 899 (5.6)% (5.5)% (0.1)% 2,614 2,842 (8.0)% (8.5)% 0.5% XARELTO US 653 635 2.7% 2.7% - 1,959 1,946 0.7% 0.7% - Intl - - - - - - - - - - WW 653 635 2.7% 2.7% - 1,959 1,946 0.7% 0.7% - OTHER US 84 115 (27.2)% (27.2)% - 276 435 (36.5)% (36.5)% - Intl 112 149 (24.3)% (23.8)% (0.5)% 378 461 (17.9)% (20.9)% 3.0% WW 197 264 (25.5)% (25.3)% (0.2)% 655 896 (26.9)% (28.5)% 1.6% TOTAL PH, ID, CVM US 1,643 1,891 (13.2)% (13.2)% - 5,428 5,700 (4.8)% (4.8)% - Intl 917 950 (3.5)% (2.5)% (1.0)% 2,826 2,828 (0.1)% (3.4)% 3.3% WW 2,560 2,843 (9.9)% (9.6)% (0.3)% 8,254 8,529 (3.2)% (4.3)% 1.1% TOTAL INNOVATIVE MEDICINE US 10,447 9,402 11.1% 11.1% - 29,297 26,655 9.9% 9.9% - Intl 6,310 6,161 2.4% 3.0% (0.6)% 19,270 17,983 7.2% 3.6% 3.6% WW 16,757 $ 15,563 7.7% 7.9% (0.2)% 48,567 $ 44,638 8.8% 7.4% 1.4% See footnotes at end of schedule % Change % Change -- 6 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS MEDTECH SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency CARDIOVASCULAR US 1,397 $ 1,306 7.0% 7.0% - 4,222 $ 3,931 7.4% 7.4% - Intl 910 908 0.2% (0.2)% 0.4% 2,866 2,698 6.2% 3.4% 2.8% WW 2,307 2,213 4.3% 4.1% 0.2% 7,088 6,629 6.9% 5.8% 1.1% ELECTROPHYSIOLOGY US 771 720 7.0% 7.0% - 2,290 2,145 6.8% 6.8% - Intl 717 698 2.8% 1.8% 1.0% 2,219 2,064 7.5% 4.3% 3.2% WW 1,487 1,418 4.9% 4.4% 0.5% 4,509 4,209 7.1% 5.6% 1.5% ABIOMED US 335 336 (0.3)% (0.3)% - 1,066 1,035 3.0% 3.0% - Intl 78 86 (10.4)% (6.5)% (3.9)% 275 256 7.2% 5.4% 1.8% WW 412 423 (2.3)% (1.5)% (0.8)% 1,340 1,291 3.8% 3.5% 0.3% SHOCKWAVE US 261 220 18.8% 18.8% - 771 659 17.0% 17.0% - Intl 64 59 9.3% 11.2% (1.9)% 194 169 14.8% 15.1% (0.3)% WW 325 278 16.8% 17.2% (0.4)% 965 828 16.6% 16.6% 0.0% OTHER CARDIOVASCULAR US 31 30 3.6% 3.6% - 96 93 3.2% 3.2% - Intl 50 65 (21.9)% (23.1)% 1.2% 177 209 (15.0)% (17.7)% 2.7% WW 81 95 (13.9)% (14.7)% 0.8% 273 302 (9.4)% (11.3)% 1.9% SURGERY US 1,070 1,031 3.7% 3.7% - 3,210 3,076 4.3% 4.3% - Intl 1,459 1,511 (3.4)% (4.2)% 0.8% 4,483 4,417 1.5% (1.6)% 3.1% WW 2,528 2,542 (0.6)% (1.0)% 0.4% 7,692 7,493 2.7% 0.8% 1.9% ADVANCED US 500 477 5.1% 5.1% - 1,476 1,411 4.7% 4.7% - Intl 654 688 (5.0)% (5.7)% 0.7% 1,991 1,991 0.0% (2.9)% 2.9% WW 1,155 1,165 (0.9)% (1.3)% 0.4% 3,467 3,402 1.9% 0.2% 1.7% GENERAL US 568 555 2.4% 2.4% - 1,733 1,666 4.0% 4.0% - Intl 805 823 (2.2)% (3.0)% 0.8% 2,492 2,426 2.7% (0.6)% 3.3% WW 1,373 1,378 (0.3)% (0.8)% 0.5% 4,225 4,092 3.3% 1.3% 2.0% See footnotes at end of schedule % Change % Change -- 7 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency VISION US 596 $ 571 4.3% 4.3% - 1,740 $ 1,694 2.7% 2.7% - Intl 865 828 4.4% 5.6% (1.2)% 2,537 2,354 7.8% 6.3% 1.5% WW 1,461 1,400 4.4% 5.1% (0.7)% 4,277 4,048 5.6% 4.8% 0.8% CONTACT LENSES / OTHER US 465 456 1.9% 1.9% - 1,378 1,337 3.1% 3.1% - Intl 588 562 4.7% 6.2% (1.5)% 1,669 1,565 6.6% 5.5% 1.1% WW 1,053 1,018 3.5% 4.3% (0.8)% 3,047 2,902 5.0% 4.4% 0.6% SURGICAL US 132 116 13.6% 13.6% - 363 358 1.4% 1.4% - Intl 276 266 3.8% 4.3% (0.5)% 867 789 10.0% 8.0% 2.0% WW 408 383 6.8% 7.1% (0.3)% 1,230 1,147 7.3% 5.9% 1.4% ORTHOPAEDICS US 1,448 1,396 3.8% 3.8% - 4,353 4,200 3.6% 3.6% - Intl 898 878 2.2% 2.9% (0.7)% 2,794 2,620 6.6% 3.5% 3.1% WW 2,345 2,274 3.2% 3.4% (0.2)% 7,146 6,820 4.8% 3.6% 1.2% HIPS US 271 262 3.5% 3.5% - 831 796 4.4% 4.4% - Intl 148 144 2.6% 3.0% (0.4)% 465 440 5.7% 2.1% 3.6% WW 419 405 3.1% 3.3% (0.2)% 1,296 1,235 4.9% 3.6% 1.3% KNEES US 221 216 2.1% 2.1% - 688 673 2.2% 2.2% - Intl 165 160 3.0% 4.4% (1.4)% 528 482 9.7% 7.1% 2.6% WW 386 377 2.5% 3.1% (0.6)% 1,216 1,155 5.3% 4.2% 1.1% TRAUMA US 555 512 8.6% 8.6% - 1,623 1,515 7.1% 7.1% - Intl 288 281 2.4% 2.8% (0.4)% 880 818 7.6% 4.4% 3.2% WW 844 793 6.4% 6.5% (0.1)% 2,504 2,333 7.3% 6.2% 1.1% SPINE, SPORTS & OTHER US 401 406 (1.2)% (1.2)% - 1,211 1,216 (0.4)% (0.4)% - Intl 296 293 1.3% 2.0% (0.7)% 920 881 4.5% 1.5% 3.0% WW 697 698 (0.1)% 0.1% (0.2)% 2,131 2,096 1.7% 0.4% 1.3% TOTAL MEDTECH US 4,512 4,306 4.8% 4.8% - 13,525 12,902 4.8% 4.8% - Intl 4,130 4,124 0.1% 0.1% 0.0% 12,679 12,089 4.9% 2.2% 2.7% WW 8,642 $ 8,430 2.5% 2.5% 0.0% 26,204 $ 24,991 4.9% 3.5% 1.4% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Includes the sales of ZYTIGA which were previously disclosed separately (4) Reported as U.S. sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely % Change % Change -- 8 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 25,399 $ 100.0 23,993 $ 100.0 5.9 Cost of products sold 8,097 31.9 7,303 30.4 10.9 Gross Profit 17,302 68.1 16,690 69.6 3.7 Selling, marketing and administrative expenses 6,285 24.7 5,922 24.7 6.1 Research and development expense 4,652 18.3 3,672 15.3 26.7 In-process research and development impairments 339 1.4 - - Interest (income) expense, net 31 0.1 18 0.1 Other (income) expense, net 5,780 22.8 (478) (2.0) Restructuring 181 0.7 63 0.3 Earnings before provision for taxes on income 34 0.1 7,493 31.2 (99.5) (Benefit from)/Provision for taxes on income (176) (0.7) 2,341 9.7 (107.5) Net earnings 210 $ 0.8 5,152 $ 21.5 (95.9) Net earnings per share (Diluted) 0.09 $ 2.12 $ (95.8) Average shares outstanding (Diluted) 2,448.6 2,428.6 Effective tax rate (517.6) % 31.2 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 7,672 $ 30.2 8,436 $ 35.2 (9.1) Net earnings 6,339 $ 25.0 6,801 $ 28.3 (6.8) Net earnings per share (Diluted) 2.59 $ 2.80 $ (7.5) Effective tax rate 17.4 % 19.4 % (1) See Reconciliation of Non-GAAP Financial Measures. THIRD QUARTER 2026 2025 -- 9 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 74,771 $ 100.0 69,629 $ 100.0 7.4 Cost of products sold 24,254 32.4 22,288 32.0 8.8 Gross Profit 50,517 67.6 47,341 68.0 6.7 Selling, marketing and administrative expenses 18,751 25.1 16,923 24.3 10.8 Research and development expense 11,832 15.8 10,413 15.0 13.6 In-process research and development impairments 375 0.5 - - Interest (income) expense, net 136 0.2 (62) (0.1) Other (income) expense, net 6,405 8.6 (7,692) (11.1) Restructuring 247 0.3 144 0.2 Earnings before provision for taxes on income 12,771 17.1 27,615 39.7 (53.8) Provision for taxes on income 1,792 2.4 5,927 8.6 (69.8) Net earnings 10,979 $ 14.7 21,688 $ 31.1 (49.4) Net earnings per share (Diluted) 4.49 $ 8.94 $ (49.8) Average shares outstanding (Diluted) 2,445.8 2,424.8 Effective tax rate 14.0 % 21.5 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 24,153 $ 32.3 24,635 $ 35.4 (2.0) Net earnings 20,034 $ 26.8 20,206 $ 29.0 (0.9) Net earnings per share (Diluted) 8.19 $ 8.33 $ (1.7) Effective tax rate 17.1 % 18.0 % (1) See Reconciliation of Non-GAAP Financial Measures. NINE MONTHS 2026 2025 -- 10 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 7.7% 2.5% 5.9% U.S. 11.1% 4.8% 9.1% International 2.4% 0.1% 1.5% WW Currency (0.2) 0.0 (0.1) U.S. - - - International (0.6) 0.0 (0.3) WW Operational 7.9% 2.5% 6.0% U.S. 11.1% 4.8% 9.1% International 3.0% 0.1% 1.8% WW Adjusted Operational Ex A&D 8.0% 2.5% 6.1% U.S. 11.1% 4.8% 9.1% International 3.2% 0.1% 1.9% Adjusted Operational Sales Growth THIRD QUARTER 2026 ACTUAL vs. 2025 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 11 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 8.8% 4.9% 7.4% U.S. 9.9% 4.8% 8.3% International 7.2% 4.9% 6.2% WW Currency 1.4 1.4 1.4 U.S. - - - International 3.6 2.7 3.2 WW Operational 7.4% 3.5% 6.0% U.S. 9.9% 4.8% 8.3% International 3.6% 2.2% 3.0% Caplyta (0.6) (0.4) U.S. (1.0) (0.7) International 0.0 0.0 All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1 U.S. 0.0 0.1 0.0 International 0.2 0.0 0.1 WW Adjusted Operational Ex A&D 6.9% 3.6% 5.7% U.S. 8.9% 4.9% 7.6% International 3.8% 2.2% 3.1% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth NINE MONTHS 2026 ACTUAL vs. 2025 ACTUAL Segments -- 12 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2026 2025 2026 2025 Net Earnings, after tax- as reported $210 $5,152 $10,979 $21,688 Pre-tax Adjustments Litigation related 5,519 15 6,116 (6,894) Intangible Asset Amortization expense 1,240 1,048 3,732 3,435 Restructuring related 1 195 168 533 302 Orthopaedics separation related 369 - 746 - Acquisition, integration and divestiture related (34) 97 142 475 (Gains)/losses on securities 10 (387) (262) (327) IPR&D impairments 339 - 375 - Other - 2 - 29 Tax Adjustments Tax impact on special item adjustments 2 (1,677) (168) (2,469) 826 Tax legislation and other tax related 168 874 142 672 Adjusted Net Earnings , after tax $6,339 $6,801 $20,034 $20,206 Average shares outstanding (Diluted) 2,448.6 2,428.6 2,445.8 2,424.8 Adjusted net earnings per share (Diluted) $2.59 $2.80 $8.19 $8.33 Operational adjusted net earnings per share (Diluted) $2.61 $8.04 Notes: 1 2 Third Quarter Nine Months Ended In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $74 million in the fiscal third quarter of 2026 ($274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs. In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $80 million were recorded in the fiscal third quarter of 2026 ($194 million Q3 2026 YTD) and $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026. In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $41 million in the fiscal third quarter of 2026 ($65 million Q3 2026 YTD) and $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. -- 13 of 17 -- Innovative Medicine Third Quarter September 27, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Third Quarter September 27, 2026 Non-GAAP Cost of products sold 4,486 $ (762) 18 (2) 3,740 Selling, marketing and admin expenses 3,035 3,035 Research and development expense 3,888 3,888 Other segment items 282 24 (92) (53) 4 165 Adjusted Income Before Tax by Segment 5,066 762 (24) - 74 55 (4) - - 5,929 MedTech Third Quarter September 27, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Third Quarter September 27, 2026 Non-GAAP Cost of products sold 3,597 $ (478) (13) (6) 3,100 Selling, marketing and admin expenses 3,014 (38) 2,976 Research and development expense 764 (5) 759 Other segment items 491 22 (339) (108) 95 (14) (320) (173) Adjusted Income Before Tax by Segment 776 478 (22) 339 121 (95) 14 369 - 1,980 Expenses not allocated to segments Third Quarter September 27, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Third Quarter September 27, 2026 Non-GAAP Cost of products sold 14 $ 14 Selling, marketing and admin expenses 236 236 Research and development expense - - Other segment items 5,558 (5,565) (6) (13) Adjusted Income Before Tax by Segment (5,808) - 5,565 - - 6 - - - (237) Johnson & Johnson Consolidated Third Quarter September 27, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Third Quarter September 27, 2026 Non-GAAP Cost of products sold 8,097 $ (1,240) 5 (2) (6) 6,854 Selling, marketing and admin expenses 6,285 (38) 6,247 Research and development expense 4,652 (5) 4,647 Other (Income) / Expense 5,780 (5,519) (19) 36 (10) (320) (52) In-process research and development impairments 339 (339) - Interest (Income)/Expense 31 31 Restructuring 181 (181) - Adjusted Income Before Tax 34 1,240 5,519 339 195 (34) 10 369 - 7,672 (Benefit from)/Provision for taxes on income (176) 239 1,230 85 37 18 - 68 (168) 1,333 Net Earnings 210 1,001 4,289 254 158 (52) 10 301 168 6,339 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date -- 14 of 17 -- Innovative Medicine Third Quarter Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Third Quarter Sept 28, 2025 Non-GAAP Cost of products sold 3,672 $ (568) (11) 3,093 Selling, marketing and admin expenses 2,869 2,869 Research and development expense 2,944 2,944 Other segment items (368) 5 (48) 174 (1) (238) Adjusted Income Before Tax by Segment 6,446 568 (5) - 59 (174) - 1 6,895 MedTech Third Quarter Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Third Quarter Sept 28, 2025 Non-GAAP Cost of products sold 3,612 $ (480) (12) (1) 3,119 Selling, marketing and admin expenses 2,801 2,801 Research and development expense 728 728 Other segment items 2 5 (156) (48) 213 (1) 15 Adjusted Income Before Tax by Segment 1,287 480 (5) 168 49 (213) - 1 1,767 Expenses not allocated to segments Third Quarter Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Third Quarter Sept 28, 2025 Non-GAAP Cost of products sold 19 $ 19 Selling, marketing and admin expenses 252 252 Research and development expense - - Other segment items (31) (25) 11 (45) Adjusted Income Before Tax by Segment (240) - 25 - (11) - - - (226) Johnson & Johnson Consolidated Third Quarter Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Third Quarter Sept 28, 2025 Non-GAAP Cost of products sold 7,303 $ (1,048) (12) (12) 6,231 Selling, marketing and admin expenses 5,922 5,922 Research and development expense 3,672 3,672 Other (Income) / Expense (478) (15) (93) (85) 387 (2) (286) In-process research and development impairments - - Interest (Income)/Expense 18 18 Restructuring 63 (63) - Adjusted Income Before Tax 7,493 1,048 15 168 97 (387) - 2 8,436 Provision for taxes on income 2,341 193 3 34 16 (87) (874) 9 1,635 Net Earnings 5,152 855 12 134 81 (300) 874 (7) 6,801 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date -- 15 of 17 -- Year to Date Innovative Medicine Nine Months September 27, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Nine Months September 27, 2026 Non-GAAP Cost of products sold 13,172 $ (2,289) (21) 10,862 Selling, marketing and admin expenses 9,083 9,083 Research and development expense 9,576 9,576 Other segment items 104 75 (274) (153) 286 38 Adjusted Income Before Tax by Segment 16,632 2,289 (75) - 274 174 (286) - - 19,008 MedTech Nine Months September 27, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Nine Months September 27, 2026 Non-GAAP Cost of products sold 11,035 $ (1,443) (55) (9) 9,528 Selling, marketing and admin expenses 8,989 (55) 8,934 Research and development expense 2,256 (7) 2,249 Other segment items 732 139 (375) (204) 31 (24) (675) (376) Adjusted Income Before Tax by Segment 3,192 1,443 (139) 375 259 (31) 24 746 - 5,869 Expenses not allocated to segments Nine Months September 27, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Nine Months September 27, 2026 Non-GAAP Cost of products sold 47 $ 47 Selling, marketing and admin expenses 679 679 Research and development expense - - Other segment items 6,327 (6,330) 1 (2) Adjusted Income Before Tax by Segment (7,053) - 6,330 - - (1) - - - (724) Johnson & Johnson Consolidated Nine Months September 27, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related Nine Months September 27, 2026 Non-GAAP Cost of products sold 24,254 $ (3,732) (55) (21) (9) 20,437 Selling, marketing and admin expenses 18,751 (55) 18,696 Research and development expense 11,832 (7) 11,825 Other (Income) / Expense 6,405 (6,116) (231) (121) 262 (675) (476) In-process research and development impairments 375 (375) - Interest (Income)/Expense 136 136 Restructuring 247 (247) - Adjusted Income Before Tax 12,771 3,732 6,116 375 533 142 (262) 746 - 24,153 Provision for taxes on income 1,792 718 1,361 93 161 63 (63) 136 (142) 4,119 Net Earnings 10,979 3,014 4,755 282 372 79 (199) 610 142 20,034 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions -- 16 of 17 -- Year to Date Innovative Medicine Nine Months Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Nine Months Sept 28, 2025 Non-GAAP Cost of products sold 11,670 $ (2,002) (24) 9,644 Selling, marketing and admin expenses 7,919 7,919 Research and development expense 8,361 8,361 Other segment items (520) 74 (275) 164 (14) (571) Adjusted Income Before Tax by Segment 17,208 2,002 (74) - 299 (164) - 14 19,285 MedTech Nine Months Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Nine Months Sept 28, 2025 Non-GAAP Cost of products sold 10,576 $ (1,433) (35) (52) 9,056 Selling, marketing and admin expenses 8,319 8,319 Research and development expense 2,052 37 2,089 Other segment items 132 (78) (267) (155) 163 (15) (220) Adjusted Income Before Tax by Segment 3,912 1,433 78 302 170 (163) - 15 5,747 Expenses not allocated to segments Nine Months Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Nine Months Sept 28, 2025 Non-GAAP Cost of products sold 42 $ 42 Selling, marketing and admin expenses 685 685 Research and development expense - Other segment items (7,222) 6,898 (6) (330) Adjusted Income Before Tax by Segment 6,495 - (6,898) - 6 - - - (397) Johnson & Johnson Consolidated Nine Months Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Nine Months Sept 28, 2025 Non-GAAP Cost of products sold 22,288 $ (3,435) (35) (76) 18,742 Selling, marketing and admin expenses 16,923 16,923 Research and development expense 10,413 37 10,450 Other (Income) / Expense (7,692) 6,894 (123) (436) 327 (29) (1,059) In-process research and development impairments - - Interest (Income)/Expense (62) (62) Restructuring 144 (144) - Adjusted Income Before Tax 27,615 3,435 (6,894) 302 475 (327) - 29 24,635 Provision for taxes on income 5,927 603 (1,541) 58 118 (73) (672) 9 4,429 Net Earnings 21,688 2,832 (5,353) 244 357 (254) 672 20 20,206 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions -- 17 of 17 --